Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
J Virol Methods ; 90(2): 153-65, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11064116

ABSTRACT

Because antibodies to the human immunodeficiency virus (HIV) are absent in the very early phase of HIV infection, there remains a slight residual risk for HIV transmission by blood donations by viremic but antibody negative donations. To shorten the diagnostic window between infection and the detection of antibodies, Enzygnost HIV Integral (Dade Behring, Germany) was developed. With this new test, HIV p24 antigen and HIV antibodies can be detected simultaneously in a single test. In a multicenter study the new screening assay has been compared with various tests that detect only HIV antibodies or HIV p24 antigen and with assays which permit a simultaneous detection of HIV antigen and HIV antibodies. The new assay showed 100% sensitivity for the detection of antibodies to HIV-1, groups M (n=1102) and O (n=55), and HIV-2 (n=289). In 23 out of 52 seroconversion panels, seroconversion was detected 2-18 days earlier with the new combined antigen/antibody test compared to single antibody tests. All samples from a viral load panel (n=451), all samples containing p24 antigen (n=302), and all but one of the cell culture supernatants (n=38) infected with various HIV-1 subtypes or HIV-2 were identified reliably by the new test. The specificity of the assay for 4002 unselected blood donors was 99.78% initially and 99.80% after retesting. Potentially interfering factors had no systematic influence on specificity. By testing for p24 antigen, which is present prior to the onset of antibody production in some cases of recent HIV infection, the new assay reduces the diagnostic window as compared to third generation screening assays, thus permitting an earlier diagnosis of HIV infection.


Subject(s)
HIV Antibodies/blood , HIV Antigens/blood , HIV Core Protein p24/blood , HIV Infections/diagnosis , HIV-1 , HIV-2 , Mass Screening/methods , AIDS Serodiagnosis/methods , Blood Donors , Enzyme-Linked Immunosorbent Assay , Evaluation Studies as Topic , HIV Infections/blood , HIV Infections/virology , Humans , Multicenter Studies as Topic , Reagent Kits, Diagnostic , Reproducibility of Results , Time Factors , Viral Load
2.
J Virol Methods ; 67(1): 85-91, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9274821

ABSTRACT

The immunodominant regions of the gp41 from 13 HIV-1 subtype O strains from Cameroon, 11 from France and one from Germany were sequenced. The amino acid sequences were compared to those of the 3 published HIV-1 subtype O isolates, ANT70, MVP-5180 and VAU. All HIV-1 subtype O isolates had a very conserved amino acid sequence in this region and showed a subtype O specific structure. Within the cysteine loop there was a positive charge of two basic amino acids, arginine and lysine. Only two strains (CM.6778 and CM.8161) showed an acidic amino acid in this loop. None of the isolates showed the same amino acid sequence in this immunodominant region. A 25 residue peptide from the immunodominant domain of gp41 of the MVP-5180 strain was synthesized, cycled to form the cysteine-loop and coated to microtiter plates. Antibody binding was detected by indirect ELISA using an enzyme labeled anti-human IgG. Out of 111 anti-HIV-1 positive specimens, collected mainly from Cameroonian HIV infected patients, only 10 were not reactive in this assay. The 42 anti-HIV-1 subtype O positive specimens gave all a reaction above cut off. Despite the diversity found in the amino acid sequences within the 25 isolates a peptide-based indirect ELISA representing the immunodominant epitope of the strain MVP-5180 successfully detected all the anti-HIV-O sera so far tested, pointing to the importance of adding such a peptide for correct identification of HIV-1 subtype O infected patients, while some assays without HIV-O specific antigens partially fail to detect all anti-HIV-O specimens.


Subject(s)
Antigenic Variation , Enzyme-Linked Immunosorbent Assay/methods , HIV Antibodies/blood , HIV Envelope Protein gp41/immunology , HIV-1/immunology , Immunodominant Epitopes/immunology , Amino Acid Sequence , Genes, env/genetics , HIV Envelope Protein gp41/chemistry , HIV Envelope Protein gp41/genetics , HIV Infections/diagnosis , HIV-1/genetics , Humans , Immunodominant Epitopes/chemistry , Immunodominant Epitopes/genetics , Molecular Sequence Data , Peptide Fragments/chemical synthesis , Peptide Fragments/metabolism , Sequence Alignment , Sequence Analysis, DNA
3.
Infection ; 23(5): 322-33, 1995.
Article in English | MEDLINE | ID: mdl-8557399

ABSTRACT

The aim of the study was to evaluate a new ELISA for detection of HIV-1, HIV-2 and HIV-1 subtype 0 (HIV-0) antibodies. The assay format is based on the antigen sandwich principle. To enable specific detection of HIV-0 antibodies, in addition to HIV-1 and HIV-2 antigens HIV-0 antigen is used for coating the solid phase and for the conjugate. The results show that all 12 HIV-0 samples tested were detected with a high degree of reactivity, as were all the 1,144 anti-HIV-1 and 424 anti-HIV-2 positive samples. The capacity of the test to enable early detection of seroconversions is equivalent to that of other sandwich ELISAs. The specificity of the assay was determined to be 99.89/99.94% (initial/after retest) using 58,366 samples, which is superior to the other ELISAs used for comparison. Even with difficult samples (i.e. samples of African origin, samples known to cause false-positive reactivity in different ELISAs, or samples containing potential interference factors) there were very few false-positive reactions. Therefore, the new assay is well suited for screening blood donations as well as for evaluating samples from patients of different geographic origin.


Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , HIV Antibodies/blood , HIV Seropositivity/diagnosis , HIV-1/immunology , HIV-2/immunology , Evaluation Studies as Topic , Humans , Predictive Value of Tests , Reagent Kits, Diagnostic , Sensitivity and Specificity
4.
J Virol Methods ; 51(2-3): 177-83, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7537751

ABSTRACT

Five anti-subtype O specimens were tested by anti-HIV-1/2 screening and confirmatory assays. They can be divided into three specimens, reactive with all ELISAs, independent of the nature of the antigen (recombinant proteins or peptides) and test configuration (indirect ELISA or double antigen/sandwich ELISA). One specimen was not detected by one peptide based ELISA. One specimen was only recognized by two ELISAs and should be considered as a marker sample for the weakness of currently used ELISAs with anti-subtype O. Three different immunoblot assays available commercially detected two of the specimens with a major binding of gp160 and other viral bands, especially the integrase and reverse transcriptase. Another two specimens lacked reactivity with glycoproteins almost completely, but showed some staining with the enzymes of HIV, and would most probably be interpreted as indeterminate. The fifth specimen, which was also missed by most of the ELISAs, had very faint staining of the gp160 and a very weak staining of p24, and would most probably be interpreted as negative. Adaption of currently available tests to anti-subtype O is needed for the future reliability of anti-HIV diagnostic reagents.


Subject(s)
AIDS Serodiagnosis , Enzyme-Linked Immunosorbent Assay , HIV Infections/diagnosis , HIV-1/immunology , Immunoblotting , Female , Gene Products, env/blood , HIV Antibodies/blood , HIV Antibodies/immunology , HIV Envelope Protein gp160 , HIV Infections/virology , HIV Reverse Transcriptase , HIV-1/classification , Humans , Male , Protein Precursors/blood , RNA-Directed DNA Polymerase/blood , Reproducibility of Results
5.
Biol Chem Hoppe Seyler ; 368(8): 991-9, 1987 Aug.
Article in English | MEDLINE | ID: mdl-3663331

ABSTRACT

The antigen-specific immune suppression by gelonin-antigen conjugates was tested in two different systems: (i) the horseradish-peroxidase-stimulated T-cell proliferation in vitro and (ii) in vivo with experimental autoimmune myasthenia gravis (EAMG) in the rat. For this, the phytotoxin gelonin, a glycoprotein from Gelonium multiflorum, was purified and linked to the respective antigens. For the in-vitro assay a lymph node cell suspension from rats immunized with horseradish peroxidase was cultured in the presence of this protein and proliferation was measured by [3H]thymidine uptake. In-vitro proliferation was significantly inhibited by adding gelonin-horseradish peroxidase conjugates. The therapeutic effects of antigen-gelonin conjugates were tested in the rat model EAMG. For these experiments rats were immunized with purified nicotinic acetylcholine receptor from electric fish in order to develop EAMG. The success of the immunization was monitored by the change in physical performance tests, the change in anti-acetylcholine receptor antibody titer, and by the change in the number of ionic endplate channels using a novel electrophysiological method. The latter method permits a very accurate assay of functional damage of acetylcholine receptor at the endplate and correlates well with the clinical severity of the disease. Rats were conventionally immunized with acetylcholine receptor from electric fish. After the onset of EAMG as measured by physical performance tests and rise in antibody titer a group of the animals was injected with an acetylcholine receptor-gelonin conjugate and this treatment was repeated seven days later. The loss in functional acetylcholine receptor was significantly smaller in the therapy group than in the untreated EAMG group.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Antigens/administration & dosage , Myasthenia Gravis/drug therapy , Plant Proteins/therapeutic use , Animals , Culture Media , Electrophysiology , Female , Immunization , Lymph Nodes/cytology , Peroxidases/immunology , Peroxidases/therapeutic use , Rats , Rats, Inbred Strains , Receptors, Cholinergic/metabolism , Ribosome Inactivating Proteins, Type 1 , Spectrometry, Fluorescence
6.
Science ; 235(4790): 787-9, 1987 Feb 13.
Article in English | MEDLINE | ID: mdl-3810165

ABSTRACT

Deregulation of c-myc expression in association with chromosomal translocations occurs in over 95% of murine plasmacytomas, rat immunocytomas, and human Burkitt lymphomas. Infection with a murine retrovirus (J-3) containing an avian v-myc rapidly induced plasmacytomas in pristane-primed BALB/cAn mice. Only 17% of the induced plasmacytomas that were karyotyped showed the characteristic chromosomal translocations involving the c-myc locus. Instead, all of the translocation-negative tumors demonstrated characteristic J-3 virus integration sites that were actively transcribed. Thus, the high levels of v-myc expression have replaced the requirement for chromosomal translocation in plasmacytomagenesis and accelerated the process of transformation.


Subject(s)
Cell Transformation, Neoplastic , Genes, Viral , Moloney murine leukemia virus/genetics , Oncogenes , Plasmacytoma/microbiology , Retroviridae/genetics , Translocation, Genetic , Animals , Birds , Mice , Mice, Inbred BALB C , Mice, Inbred Strains , Nucleic Acid Hybridization , Plasmacytoma/genetics , Transcription, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...